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Summary Background: Data on imported malaria in pregnant women are scarce.
Method: A retrospective, descriptive study of pooled data on imported malaria in pregnancy
was done using data from 1991 to 2014 from 8 different collaborators in Europe, the United
States and Japan. National malaria reference centres as well as specialists on this topic were
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asked to search their archives for cases of imported malaria in pregnancy. A total of 631 cases
were collated, providing information on Plasmodium species, region of acquisition, nationality,
country of residence, reason for travel, age, gestational age, prophylactic measures and treat-
ment used, as well as on complications and outcomes in mother and child.
Results: Datasets from some sourceswere incomplete. The predominant Plasmodium specieswas
P. falciparum (78.5% of cases). Among the 542 cases where information on the use of chemopro-
phylaxiswas known, 464 (85.6%) did not use chemoprophylaxis. Themain reason for travellingwas
“visiting friends and relatives” VFR (57.8%) and overall, most cases ofmalariawere imported from
West Africa (57.4%). Severe anaemia was the most frequent complication in the mother. Data on
offspring outcome were limited, but spontaneous abortion was a frequently reported foetal
outcome (nZ 14). A total of 50 different variants of malaria treatment regimens were reported.
Conclusions: Imported cases of malaria in pregnancy are mainly P. falciparum acquired in sub-
Saharan Africa. Malaria prevention and treatment in pregnant travellers is a challenge for travel
medicine due to few data onmedication safety andmaternal and foetal outcomes. International,
collaborative efforts are needed to capture standardized data on importedmalaria cases in preg-
nant women.
ª 2015 Elsevier Ltd. All rights reserved.
1. Introduction
Malaria in pregnancy is an important cause of maternal and
foetal morbidity and is a potentially life-threatening
infection [1]. In particular, non-immune pregnant women
have an increased risk of both complications and a more
severe course of the infection [2,3]. Additionally, pregnant
women are more attractive to Anopheles mosquitoes
compared to non-pregnant women although the mecha-
nisms for this are poorly understood [4]. More than 80
million travellers visit malaria-endemic areas annually [5].
A significant proportion of travellers are women of child-
bearing age. In 2012, pregnant women constituted 6% of the
women with imported malaria in the United States [6].
Pregnant travellers to malaria risk areas should use per-
sonal protection measures and in high-risk areas, chemo-
prophylaxis is also indicated. In general, few data exist on
the number and proportion of pregnant travellers or women
who become pregnant while visiting malaria endemic areas;
on the geographic region where they acquired their ma-
laria; the reason for travel; chemoprophylaxis, preventive
measures and malaria treatments used. For ethical and
safety reasons, there are few studies on malaria treatment
in pregnant women and there is little information on out-
comes for mother and foetus in the context of imported
malaria defined as malaria presenting in a non-endemic
area, having being acquired during travel or associated
with immigration from a malaria-endemic region.
The goals of our study were to evaluate cases of im-
ported malaria in pregnant women and to ascertain
maternal and child outcomes, as well as the type of travel
associated with infection acquisition (Visiting Friends and
Relatives (VFR), tourism, immigration) and the preventive
measures and treatments used.
2. Methods
We conducted a retrospective descriptive analysis of preg-
nant women who were diagnosed with laboratory confirmed
malaria in non-endemic, industrialized countries. In order to
create a comprehensive database, we asked authors of pa-
pers on the subject of malaria, as well as national malaria
reference centres if they would search their archives for
cases of malaria in pregnant women. Cases were contributed
by two reference centres; the Centers for Disease Control
and Prevention in the United States and the Malaria Refer-
ence Laboratory in the UK and from single centres in France,
Spain, Sweden, Japan, Austria and the Netherlands. The
cases provided by the reference centres were cases of im-
portedmalaria in pregnantwomen that hadbeen reportedby
physicians countrywide. The cases provided by the single
centreswere locally collated data of cases presenting to that
particular centre. Some of these cases have been previously
published. This concerns the data provided from Madrid as
well as some of the cases from Marseille [33,46].
We requested the following data elements; number of
pregnant women with imported malaria; age; Plasmodium
species, country of infection acquisition and the patient’s
nationality; theweek of gestation at time of onset ofmalaria
symptoms; complications concerning the mother (such as
cerebral malaria; pulmonary oedema or acute respiratory
distress syndrome; circulatory collapse; acute renal failure;
hepatic failure; coagulopathy and/or disseminated intra-
vascular coagulation (DIC); severe anaemia; hypoglycaemia;
metabolic acidosis); pregnancy outcome (foetal death, low
birth weight, intrauterine growth retardation, stillbirth,
spontaneous or therapeutic abortion, pre-term, congenital
malaria, healthy). Furthermore we inquired about the
reason for travel (tourism; visiting friends and relatives
(VFR); immigration; business etc.) and preventive measures
used during travel (details of chemoprophylaxis; bed nets;
protective clothing; repellents) as well as information on the
antimalarial treatment used. Cases reported in the period
1991e2014 were included. All data were anonymised.
3. Results
3.1. Number of cases (Table 1)
We collated a total number of 631 cases of imported ma-
laria in pregnancy from areas where malaria is non-
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endemic; USA: n Z 425, UK: n Z 113, Marseille: n Z 40,
Madrid: nZ 19, Stockholm: nZ 15, Japan: nZ 9, Vienna:
nZ 5 and Amsterdam: nZ 5. Availability of requested data
parameters varied between sites. Plasmodium species
identification was largely complete. Epidemiological and
demographic data were available from 8 sites and some
clinical obstetric data from 7 sites.
The mean age for the entire study population, where
this information was available was 29.6 years.
Data were scarce with regard to the gestational age, but
out of 127 women, 46 women (36%) were in their third
trimester at malaria diagnosis, 49 women (38.6%) were in
their second trimester and 30 women (23.6%) were in their
first trimester. There were 2 cases of malaria diagnosed
post-partum.
3.2. Plasmodium species (Table 1)
The majority of cases (n Z 454, 78.5% of all 578 cases
where this information was available) were diagnosed with
Plasmodium falciparum malaria.
The second most frequent malaria species was Plasmo-
dium vivax (n Z 92, 15.9%).
The remaining cases were diagnosed with Plasmodium
ovale (n Z 15, 2.6%), Plasmodium malariae (n Z 10, 1.7%)
and 7 cases of mixed infection. The Plasmodium species
listed by reporting centre are shown in Fig. 1.
3.3. Region of malaria acquisition (Table 2)
Of the 610 patients for whom information was available on
the geographic region of malaria acquisition (according to
UN criteria; [7]), in 524 cases (85.9%), Africa was the
continent where they acquired their malaria; with West
Africa (e.g. Nigeria, Ghana, Sierra Leone) being the UN-
region with most infection acquisitions (n Z 351, 57.4%).
Most women diagnosed with imported malaria in the United
States and the United Kingdom fell into this category. In
Marseille, however, most cases were imported from East
Africa, more specifically from the Comoros Union.
86 women (14%) acquired malaria in East Africa (e.g.
Comoros, Uganda, Kenya), followed by 67 cases (10.9%) of
Table 1 Demographic characteristics and Plasmodium
species reported.
Variables Number
Pregnant
Women
n Z 631a
Age Unknown n Z 11
Mean ageb (years) 29.6
Range (years) 13e51
Gestational
Age
Unknown n Z 504
1st Trimester 23.6% (n Z 30)
2nd Trimester 38.6% (n Z 49)
3rd Trimester 36.2% (n Z 46)
Post-Partum 1.6% (n Z 2)
Plasmodium
Species
Unknown 8.4% (n Z 53)
Plasmodium falciparum 72% (n Z 454)
Plasmodium vivax 14.6% (n Z 92)
Plasmodium malariae 1.6% (n Z 10)
Plasmodium ovale 2.4% (n Z 15)
Mixed P. falciparum/
P. vivax
0.16% (n Z 1)
Mixed P. falciparum/
P. malariae
0.32% (n Z 2)
Mixed P. falciparum/
P. ovale
0.32% (n Z 2)
Mixed P. vivax/P. ovale 0.32% (n Z 2)
a Includes 2 cases where malaria was diagnosed post-partum.
b Madrid and Marseille only provided the mean age for their
patients.
Fig. 1 Plasmodium species by reporting centre.
302 A.K. Ka¨ser et al.
infection acquisition in Middle Africa (e.g. Cameroon,
Equatorial Guinea) and 47 cases (7.7%) in South Asia (e.g.
India, Pakistan).
Twenty four pregnant women (3.9%) were infected in
Central America (Honduras, Guatemala). Only a few cases
of malaria acquisition occurred in the Caribbean (n Z 7,
1.1%), South America (n Z 5, 0.8%), North Africa (n Z 5,
0.8%), Southern Africa (n Z 5, 0.8%), South-East Asia
(n Z 2, 0.3%) and Melanesia (n Z 1, 0.2%).
3.4. Reason for travel
The most common reason for travel was visiting friends and
relatives (n Z 306, 57.8%). Another 130 women (24.6%)
were refugees or recently immigrated. Twenty patients
(3.8%) travelled for “tourism”. Other reasons for travel
were student or teacher activities (n Z 16), business
(n Z 13), missionary duties (n Z 6), military (n Z 1) or
working in an airline or ship (n Z 1). In many cases
(n Z 102), the reason for travel was not stated in the
clinical data.
3.5. Use of chemoprophylaxis (Table 3)
Among the 542 pregnant patients for whom this information
was available, the majority (n Z 464, 85.6%) did not use
chemoprophylaxis. This was true for 313 (83.7% of 374) US-
cases and for 74 women in the United Kingdom (91.4% of 81
cases for which this data were available). Among the 130
refugees or migrants, five reported use of chemoprophy-
laxis (chloroquine: n Z 1, primaquine: n Z 1, pyrimeth-
amine: n Z 1, drug unknown: n Z 2). For 89 women it is
unclear if chemoprophylaxis was taken.
Among the 78 women (14.4%) who were reported to have
taken chemoprophylaxis, eleven women were classified to
have used incorrect (n Z 9) or incomplete (n Z 2)
chemoprophylaxis, including one woman who had taken
“herbs” as a prophylaxis. However, our analysis showed
among the women using chloroquine and/or proguanil, in
an additional 24 cases, this can be considered “incorrect
chemoprophylaxis” in view of the region of acquisition and
the spread of chloroquine resistance.
The preferred drug for malaria prevention was chloro-
quine (n Z 26; 33.3% out of 78 patients who used chemo-
prophylaxis). Ten women (12.8%) were taking mefloquine
(one woman was at 15 weeks of pregnancy, in the other 9
cases the gestational age is unknown. No adverse preg-
nancy outcomes were documented among the 10 women
using mefloquine prophylaxis). Two women (2.6%) used
doxycycline; one of whom suffered a miscarriage (gesta-
tional age unknown). In the other case, doxycycline was
given postpartum. In 1 case, prophylaxis with atovaquone/
proguanil was used; this patient was at 20 weeks gestation
and suffered a P. vivax relapse. The pregnancy outcome
was documented as “good”. Other regimens used for
chemoprophylaxis were pyrimethamine (n Z 6), pyri-
methamine/sulfadoxine (n Z 4), chloroquine/proguanil
(nZ 2), proguanil (nZ 3), primaquine (nZ 1) and in three
cases, malaria treatment medications were incorrectly
used as prophylaxis e artesunate (nZ 2), and arthemeter/
lumefantrine (n Z 1).
3.6. Outcome of mother and child
No maternal deaths were reported but information on
outcomes was largely incomplete. 46 women were classi-
fied as having ‘severe malaria’.1 In an additional 7 cases,
the reason for being classified as severe malaria was not
Table 2 Regions of malaria acquisition listed by reporting
institutions.
CDC
na
PHE
MRL
n
Marseille
n
Other
n
Total
N Z 610
n (%)
East Africa 26 16 37 7 86 (14.1%)
Middle Africa 47 5 0 15 67 (11.1%)
North Africa 4 1 0 0 5 (0.8%)
Southern Africa 5 0 0 0 5 (0.8%)
West Africa 250 71 3 27 351 (57.4%)
Caribbean 7 0 0 0 7 (1.1%)
Central America 24 0 0 0 24 (3.9%)
South America 4 0 0 1 5 (0.8%)
South Asia 39 8 0 0 47 (7.7%)
South-East Asia 1 0 0 1 2 (0.3%)
Melanesia 1 0 0 0 1 (0.16%)
a In 10 US-cases the continent Africa was stated as region of
acquisition without being further specified.
Table 3 Malaria chemoprophylaxis used by pregnant
women diagnosed with malaria.
Total N Z 542
n (%)
No chemoprophylaxis 464 (85.6%)
Chemoprophylaxis useda 78 (14.4%)
Chloroquine 26 (4.8%)
Chloroquine þ proguanil 2 (0.4%)
Proguanil 3 (0.6%)
Atovaquone þ proguanil 1 (0.2%)
Mefloquine 10 (1.8%)
Doxycycline 2 (0.4%)
Primaquineb 1 (0.2%)
Pyrimethamine 6 (1.1%)
Sulfadoxine þ pyrimethamine 4 (0.7%)
Artesunate* 2 (0.4%)
Artemether þ lumefantrine* 1 (0.2%)
“Herbs” 1 (0.2%)
Chemoprophylaxis used
but medication unknown
19 (3.5%)
* Used as “prophylaxis” not treatment.
a Including eleven cases where chemoprophylaxis was classi-
fied as incorrect or incomplete.
b Primaquine is contraindicated in pregnancy, as it can cause
acute haemolysis in patients with glucose-6-phosphate dehy-
drogenase deficiency and it is not feasible to test the unborn for
G6PD deficiency. 1 Severe malaria was defined according to WHO criteria [8].
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Table 4 Guidelines on anti-malarial chemoprophylaxis for pregnant women by different countries/institutions.
Centers for disease control and prevention [9] Public Health England [10] France [11]
Atovaquone-
proguanil
Cannot be used for women who are pregnant or
breastfeeding a child that weighs >5 kg.
Should not be used in pregnancy because of lack of evidence on
safety in pregnancy. However, if there are no other options, use
may be considered in second and third trimesters after risk
assessment. Inadvertent use is no indication to consider
termination of the pregnancy. Should be avoided by breastfeeding
women but can be used if no suitable alternative antimalarial.
May be considered if travel
to areas with chloroquine-
resistance and areas with
multidrug-resistance cannot
be deferred.
Chloroquine Can be used in all trimesters of pregnancy, but restricted to
areas where there is no chloroquine or mefloquine
resistance.
Safe in all three trimesters. Only in regions without drug-
resistance.
Safe in pregnant women.
Doxycycline Cannot be used in pregnant women and children <8 years. Best avoided during pregnancy. But if required before 15 weeks’
gestation it should not be withheld if other options are unsuitable.
The regimen must be completed before 15 weeks’ gestation
though (including 4 weeks after travel) (UK National Teratology
Information Service, see toxbase.org).
Contraindicated in the
second and third trimester.
Not recommended in the
first trimester.
Mefloquine Can be used in all trimesters of pregnancy. Cannot be used
in areas with mefloquine-resistance. Cannot be used in
certain neuropsychiatric disorders.
Caution in first trimester, but can be used in all trimesters for
travellers to highly endemic areas. It seems unlikely that
mefloquine is associated with adverse foetal outcomes.
Inadvertent use does not constitute an indication to terminate
pregnancy.
Recommended for pregnant
women travelling to areas
with elevated chloroquine-
resistance and/or
multidrug-resistance.
Primaquine Cannot be used in pregnant women. Cannot be used in
patients with G6PD-deficiency. Cannot be used in
breastfeeding women unless baby has also been tested for
G6PD-deficiency. Only for areas with principally P. vivax.
No information. No information.
Proguanil No information. Caution in pregnancy. Folic acid 5 mg daily required at least during
first trimester. Mostly used in combination with other drugs. As
monotherapy, only for regions without chloroquine-resistance and
if chloroquine cannot be used for that particular patient.
Combination chloroquine-
proguanil recommended for
pregnant women travelling
to chloroquine-resistant
areas.
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apparent as no complications were reported, but the
women were treated with i.v.-quinidine which was used as
a treatment for complicated malaria.
Some 235 women had no reported malaria complications
(Table 5). Of a total of 54 reported maternal malaria
complications (several complications possible per individual
case), the most frequent were severe anaemia with a
measured haemoglobin of 7 g/dl or less (n Z 22).
One patient suffered from circulatory shock with a sys-
tolic blood pressure <70 mm Hg. The patient survived but
no details were available. Four cases of hypoglycaemia
were reported, but they were asymptomatic and above the
WHO cut-off for severe malaria (glucose >40 mg/dl). One
patient was reported to have tachypnoea, but neither
pulmonary oedema/ARDS nor metabolic acidosis were re-
ported for this patient. Hyperparasitaemia over 5% was
reported in eight cases, with another seven cases with a
parasitaemia within the range of 1e4%.
Other laboratory and clinical findings were mild or
moderate anaemia (Hb 7e11 g/dl, n Z 82); thrombocyto-
penia (platelet count <150.000/ml; n Z 38); thrombosis
(n Z 3); splenomegaly (n Z 7) and/or hepatomegaly
(n Z 3).
There were also 12 other complications noted, such as
hypertension; gestational diabetes; thrombosis; and non-
specified complications.
Concerning the offspring, few data were available (Table
6). Among the 95 cases where data on outcome of the
offspring was available, 51/95 (53%) children were consid-
ered healthy. In 9/95 (9.5%), cases child health at birth was
documented as good. 10/95 children (10.5%) were deliv-
ered pre-term, one by caesarean section in the 35th
gestational week because of threatening intrauterine
asphyxia; the baby was reported to have continuing
bradycardia and there was a lack of uterine contractions. In
three cases, intrauterine growth retardation occurred and
one baby was reported to have a low birth weight <2500 g.
Of 16 abortions (16.8% of 95 cases), 14 occurred sponta-
neously whereas 2 were therapeutically induced. One of
the therapeutic abortions was unrelated to the malaria
episode, the other was conducted because of foetal mal-
formations: the mother suffered severe P. falciparum ma-
laria in the 18th week of pregnancy some two days after
returning from a 35-day trip to Zambia to visit friends and
relatives. She was reported to have taken chemoprophy-
laxis before admission, but the exact drug remained un-
clear. Two cases of congenital malaria were documented.
3.7. Treatment (Table 7)
Fourteen women received blood transfusions and an addi-
tional two women were supported by exchange transfusion
therapy.
Amongst the 50 different treatment regimens reported in
this study population, the most frequent was the combina-
tion of quinine or quinidine plus clindamycin (administered
160 times). Chloroquine as monotherapy was the second
most frequent (nZ 56). Monotherapy with quinine or quin-
idine was administered in 84 cases. Quinine or quinidine plus
tetracycline was given in 37 cases. Mefloquine (n Z 24),
atovaquone plus proguanil (n Z 14) and chloroquine plus
primaquine (nZ 13); in five cases, it was clearly stated that
primaquine was administered post-partum. The other ther-
apeutic regimens and combinations are listed in Table 7.
4. Discussion
Our retrospective analysis included 631 women who pre-
sented with travel-associated malaria in 8 non-endemic
countries. Although data are incomplete, they show that
the main species was P. falciparum, the main source of
malaria was sub-Saharan Africa, that the majority of the
women did not use chemoprophylaxis and that there was no
standardization of treatment as shown by a total of 50
different treatment regimens.
The treatment of malaria in pregnant travellers or in
women who become pregnant whilst travelling to a
malaria-endemic region poses important challenges for
clinicians. Safety is an issue and data on the pharmacoki-
netics of therapeutic drugs in pregnancy are incomplete.
Due to an increased volume of distribution and other
physiological changes in pregnancy, there may be altered
drug metabolism and therefore the need to optimize dos-
ages for pregnant women. This is exemplified by dihy-
droartemisinin and artemether. Pregnant women both were
shown to have lower plasma concentrations of dihy-
droartemisinin (active metabolite) compared to non-
Table 5 Clinical features of P. falciparum malaria in the
mother.a
Uncomplicated malaria Number n
No complications reported 235
Jaundice 2
Prostration 2
Complicated malaria Number n
Severe malariab 46
Neurological impairment/coma 2
Pulmonary oedema/acute respiratory distress
syndrome (ARDS)
13
Acute renal Fl Fis ualsly women?cliniciansf
which 44 had severe malaria?immigrantsn
since here only includes thos who turned up
as cases ailure (Creatinine >265 mmol/l)
5
Severe anaemia (Hb <7 g/dl) 22
Coagulopathy and/or disseminated
intravascular coagulationc
2
Circulatory shock (systolic blood pressure
<70 mm Hg)
1
Hypoglycemia (above WHO cut-off level for
severe malaria)
4
Respiratory distress, hyperventilation
(without acidosis)
1
a There were no data available on complications in the mother
from UK data.
b In an additional 7 cases, the reason for being classified as
severe malaria was not apparent as no complications were re-
ported, but the women were treated with i.v.-quinidine which
was used as a treatment for complicated malaria.
c In 1 case, disseminated intravascular coagulation was
considered to be associated with stillbirth rather than the ma-
laria episode.
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pregnant adults. This finding was accompanied by a lower
cure-rate of the malaria infection [14].
Diagnosis of falciparum malaria in pregnancy can be
confounded by sequestration of parasites in the placenta,
which can lead to a parasite count in the peripheral blood
below the threshold for microscopic detection in blood
films, with possible delayed diagnosis [1,15]. Additionally,
pregnant women often experience a more severe course of
the infection than non-pregnant women [2,3]. P. falcipa-
rum and less often P. vivax are known to cause adverse
pregnancy outcomes, such as miscarriages, low birth weight
due to intrauterine growth retardation or preterm delivery,
and maternal anaemia [8,16e18]. While Plasmodium
knowlesi malaria is rare during pregnancy, especially
compared to P. falciparum, it may be associated with
preterm delivery, low birth weight and maternal anaemia
[19]. Little is known regarding the impact of P. ovale and P.
malariae on pregnancy. In our study, there were 46 cases
designated as “severe malaria” (mainly P. falciparum (36
cases) and 5 cases of single P. vivax infection and five un-
known) and, although we have limited detailed informa-
tion, a total of 54 complications were recorded including
cerebral malaria, severe anaemia, pulmonary oedema and
ARDS. Two of the women received exchange blood trans-
fusion. Four patients were reported as being admitted to
intensive care, which seems an underestimate as 46 cases
of severe malaria were reported. In the four afore-
mentioned cases, the reasons for admission to intensive
care were disseminated intravascular coagulation, cerebral
malaria, post-operative bleeding after caesarean section
and hypotension.
Overall, P. falciparum was the main species to cause
malaria in the study population. The highest percentage of
vivax malaria was recorded in the United States, whereas
the lowest was documented in France. This indicates
greater importation of P. vivax malaria into the United
States compared to European countries, reflecting a higher
rate of acquisition of malaria in South and/or Central
America and India since these are important travel desti-
nations for US travellers. Most women acquired their ma-
laria infection in sub-Saharan Africa, which in the context
of non-imported malaria is still the region where the ma-
laria burden is greatest [20].
Prevention of malaria in pregnant women is problematic
and travel should be deferred if possible [10]. Few studies
have evaluated the safety of malaria chemoprophylaxis for
pregnant women or the unborn child [21,22]. Current in-
ternational guidelines on the use of chemoprophylaxis are
summarized in Table 4. While chloroquine (as monotherapy
or in combination with proguanil) is considered safe and
effective in all trimesters of pregnancy [22], its usefulness
is limited to areas where P. vivax is predominant and re-
mains sensitive to this drug. P. falciparum, which is the
main agent responsible for causing severe and sometimes
fatal malaria is resistant to chloroquine in many regions.
Mefloquine can be recommended for pregnant women
travelling to an area with chloroquine-resistant P. falcipa-
rum [9,10,21], but prospective use in the first trimester has
been reported in only two studies in malaria-endemic areas
[23,24]. Limited data are available from a retrospective
case series [25]. No prospective studies have been done in
travellers. However, a drug safety database analysis
showed no excess of neonatal malformations or mis-
carriages after mefloquine exposure (in prophylactic doses)
in early pregnancy [21]. Additionally, the US FDA reviewed
non-published data sources and also arrived at the
conclusion that mefloquine was safe in all trimesters of
pregnancy. Mefloquine should not be prescribed in the
presence of a history of neuropsychiatric disorders such as
seizures, affective disorders or psychosis. For travel to the
border of ThailandeLaos, ThailandeCambodia, Myan-
mareLaos and ChinaeMyanmar there are currently no safe,
effective chemoprophylactic drugs for pregnant women as
these areas are considered multi-drug-resistant areas [26].
The use of atovaquone-proguanil in pregnancy is still
subject to debate, although the data on the individual
components are reassuring and in some countries this pro-
phylaxis is recommended [11]. It is likely that there have
been many instances of inadvertent atovaquone-proguanil
use before the patient discovered that she was pregnant.
Analysing the data on the birth outcomes from these in-
stances would be useful to assess the safety of atovaquone-
proguanil use during pregnancy. Doxycycline is considered
contraindicated by most authorities, since it may cause
discolouration of the child’s primary teeth if given during
pregnancy [27]. Other studies also suggest a transient in-
hibition of bone growth in the newborn and unborn child
[28]. In the UK guidelines for malaria prevention [10],
doxycycline is considered best avoided during pregnancy.
However, it is not absolutely contraindicated and may be
considered as a possible prophylaxis during the first 15
weeks, if other options are unsuitable. Importantly, it is
emphasized that the regimen must be concluded before 15
weeks’ gestation. In Sweden, doxycycline can be recom-
mended as chemprophylaxis during the first trimester. This
evaluation is supported by data from the Swedish medical
birth register, where 1809 women were exposed to tetra-
cyclines during early pregnancy and where no excess of
malformations was found compared to a control group with
no exposure [29]. Primaquine is contraindicated in preg-
nancy, as it can cause acute haemolysis in patients with
glucose-6-phosphate dehydrogenase deficiency and it is not
feasible to test the unborn for G6PD deficiency.
Our data highlight infrequent use of chemoprophylaxis.
The majority of the pregnant women travelling who were
Table 6 Outcome of offspring.a
Type of complication Number n
No information 536
Healthy 51
Intrauterine foetal death 1
Intrauterine Growth Retardation (IUGR) 3
Low birth weight <2.5 kg 1
Pre-Term 10
Stillborn 1
Therapeutic Abortion 2
Spontaneous Abortion 14
Foetal distress 2
Congenital malaria 2
a No outcome data were available from the UK. Also, in many
other cases there was no information available on the outcome
of the offspring.
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subsequently diagnosed with malaria did not use chemo-
prophylaxis (85.6% of the women for whom this information
was available). The reasons for this practice are probably
caused by multiple factors. Some pregnant women may not
have been aware of their pregnancy or may have foregone
chemoprophylaxis because of concerns about possible
adverse drug effects on the unborn child. Other risk factors
may be socio-culturally determined: Travellers visiting
friends and relatives in their country of origin (VFRs) have
been shown to be a major risk group for imported malaria in
several studies [30e33]. This was confirmed in our study, as
VFR travellers account for a significant fraction of our study
population (57.8%). VFR travellers may mistakenly believe
that previous, partial immunity protects them from the
disease [34] which is true with regard to protection against
severe disease [35]. The cost of the chemoprophylaxis is
also believed to be a discouraging factor for some VFRs
[36].2
VFR travellers should be reminded that they need to
take full preventive precautions. Since many VFRs do not
seek pre-travel advice, they should also be targeted by the
public health system including obstetricians. The Centers
for Disease Control and Prevention recommends targeted
messages for travellers according to peak travel seasons
[6].
After VFRs, the second largest sub-group with imported
malaria were refugee women or recent migrants. Screening
may be an option here to detect malaria cases [37]. It
should be taken into account that these women would not
have used typical chemoprophylaxis regimen. However, in
some countries with moderate or high malaria transmission,
intermittent preventive treatment via administration of
sulfadoxine/pyrimethamine (SP) during pregnancy is rec-
ommended by WHO [20].
Among the women in our study population who did use
chemoprophylaxis, chloroquine and/or proguanil was most
Table 7 Antimalarial treatments or combinations
including sequential combinations used.
Treatment Number n
No information 155
No treatment 3 (1 refused
treatment)
Quinine 49
Quinine/quinidine 35
Quinine þ artesunate 1
Quinine þ clindamycin 59
Quinidine þ clindamycin 11
Quinine/quinidine þ clindamycin 90
Quinine þ primaquine 2 (in 1 case
primaquine given
after delivery)
Quinine þ clindamycine þ artesunate 1
Quinine þ clindamycine þ artemether
þ lumefantrine
1
Quinine þ doxycycline þ artesunate 1
Quinine/quinidine þ primaquine
þ tetracycline
2
Quinine/quinidine þ clindamycin
þ tetracycline
1
Quinine/quinidine þ pyrimethamine 11
Quinine/quinidine þ tetracycline 21
Quinine þ doxycycline 16
Chloroquine 56
Chloroquine þ quinine 1
Chloroquine þ quinidine 1
Chloroquine þ quinine/quinidine 3
Chloroquine þ quinine þ clindamycin 2
Chloroquine þ quinine/
quinidine þ clindamycin
5
Chloroquine þ quinine þ quinidine
þ clindamycin
1
Chloroquine þ quinine/quinidine
þ pyrimethamine
2
Chloroquine þ quinine/quinidine
þ clindamycin þ pyrimethamine
1
Chloroquine þ primaquine
þ mefloquine
1
Chloroquine þ primaquine
þ quinine/quinidine
2
Chloroquine þ primaquine
þ doxycycline
1
Chloroquine þ primaquine 13 (in 5 cases
primaquine
given postpartum)
Chloroquine þ mefloquine 2
Chloroquine þ clindamycin 1
Chloroquine þ pyrimethamine 2
Tetracycline 3
Clindamycin 3
Mefloquine 24
Mefloquine þ clindamycin 1
Mefloquine þ clindamycin
þ quinine/quinidine
2
Mefloquine þ primaquine 2
Mefloquine þ quinine/quinidine 3
Mefloquine þ quinine/quinidine
þ tetracycline
1
Table 7 (continued )
Atovaquone þ proguanil 16
Atovaquone þ proguanil
þ doxycycline
2
Atovaquone þ proguanil
þ quinine þ quinidine
1
Atovaquone þ proguanil þ chloroquine 1
Atovaquone þ proguanil þ clindamycin 1
Pyrimethamine 2
Sulfadoxine þ pyrimethamine 1
Artemisinine þ lumefantrine 7
Arthemeter followed by artesunate 1
Artesunate 3
Artesunate followed by arthemeter
þ lumefantrine
2
Artesunate þ clindamycin 2
Primaquine 1
2 It should be noted that some of these medications are not
recommended for use during pregnancy or are not actual recom-
mended regimens or may have been used sequentially.
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frequently used. However, many of these women travelled
to chloroquine-resistant P. falciparum and/or chloroquine-
resistant P. vivax areas. A recent drug utilization study by
Bloechliger et al. suggested that chloroquine-based regi-
mens are disproportionally often prescribed by GPs rela-
tively inexperienced in travel medicine [38]. It is however,
important to point out that antimalarial prophylaxis rec-
ommendations and resistance patterns have changed dur-
ing the time frame of the study (1991e2014).
Data on the use of protection against mosquito bites
such as repellents, impregnated bed nets and clothing were
largely unavailable. For pregnant women travelling to areas
of drug-resistant Plasmodium species and for long-term
travellers, personal protection measures against mosqui-
toes constitute a fundamental part of malaria prevention.
The use of insecticide-treated bed nets and the application
of DEET-repellents are considered safe and should be rec-
ommended to all pregnant travellers visiting malaria-
endemic areas as well as protective clothing and air-
conditioned or screened sleeping areas [20,39]. It should
be noted that no studies exist on the use of DEET in women
in the first trimester, or on the use of other repellents such
as Icaridin or IR3535 in pregnancy [40], but based on
experience, DEET is recommended by experts even in the
first trimester [9,10].
A total of 50 treatment regimens were reported in our
analysis. Data on the safety and efficacy of the use of
malaria treatment in pregnant travellers are scarce. There
are guidelines available (Table 8). Combinations of arte-
misinin or its derivatives with other antimalarials (ACT) are
considered the most effective antimalarial drugs to date
and are generally well tolerated [41], but difficult to
evaluate in pregnant women for safety and ethical reasons.
Data from animal studies suggest that high doses of
artemisinins in the first trimester are teratogenic [42,43]. A
recent observational study on first trimester exposure to
artemetherelumefantrine did not indicate an excess of
perinatal mortality, preterm deliveries or low birth weights
compared to pregnant women who were exposed to sulfa-
doxineepyrimethamine and/or quinine. Additionally, neu-
rodevelopmental parameters up to twelve months were
similar compared to the control-group [44].
McGready and colleagues suggest that the potential risk
of miscarriage with the use of artemisinin antimalarials in
early pregnancy may be comparable with pregnant women
treated with chloroquine or quinine and women who had no
malaria during pregnancy [16]. Currently, in Europe, a
pregnancy registry for the new EMA-registered malaria
treatment, dihydroartemisinin-piperaquine has been
established, recording malaria treatment outcomes after
use in pregnant women and their infants up to the age of
twelve months [45]. Included are women who take this
combination within the time frame of one month before or
at any time in pregnancy from conception onwards, and
also women whose partner took this drug within one month
before conception. If healthcare professionals are made
aware of this registry and collaborate in reporting, then the
register will be a valuable source of prospective surveil-
lance data on the safety profile of this ACT in pregnancy e
Pregnancy Register [45].
A major strength of our study is the large number of
cases collected from various contributing institutions in
non-endemic countries all over the world, and the pio-
neering character of this undertaking, as systematic data
collections on this topic are scarce. One considerable lim-
itation, however, was the largely incomplete datasets,
especially on pregnancy outcomes. Additionally, follow-up
until birth and thereafter to detect potential low birth
Table 8 International recommendations for malaria treatment in pregnancy.
WHO [12] ESGCP [13]
Uncomplicated falciparum
malaria in 1st trimester
First line: quinine þ clindamycin or quinine
monotherapy if clindamycin is not available
(artesunate þ clindamycin if this treatment
fails)
First line: quinine þ clindamycin or quinine
monotherapy if clindamycin is not available
Uncomplicated falciparum
malaria in 2nd and 3rd
trimester
Artemisinin-based combination therapy (ACT)
known to be effective in the region where
malaria was acquireda or
artesunate þ clindamycin or
quinine þ clindamycin
First line: artemether-lumefantrine
Second line: quinine þ clindamycin, quinine
monotherapy or mefloquine
Complicated falciparum
malaria in 1st trimester
Artesunateb First line: i.v. quinine
Complicated falciparum
malaria in 2nd and 3rd
trimester
Artesunateb First line: i.v. artesunate
Second line: i.v. quinine
P. ovale, P. malariae und
P. vivax
Chloroquine in uncomplicated cases.
Artesunate for complicated P. vivax malaria.
Primaquine for treatment of liver-stages of P.
ovale and P. vivax is contraindicated during
pregnancy
First line: in all trimesters oral chloroquine
Second line: in 2nd and 3rd trimester oral ACT
a Excluded is dihydroartemisinin-piperaquine due to current insufficient data on use in pregnancy.
b If artesunate is not available in later pregnancy, WHO considers artemether preferable to quinine as quinine is associated with an
elevated risk for hypoglycaemia [8].
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weight, malformations or gestational age at birth were
practically non-existent and do not allow for a conclusion
on possible adverse effects of chemoprophylaxis or treat-
ment on the pregnancy. It can be speculated that most
women would only have been seen by malaria/infectious
disease specialists at the time of their infection, and
thereafter returned to the care of their obstetricians for
birth and follow-up. Also, a large number of our cases were
contributed by national malaria reference centres, which
often receive limited information on cases. Furthermore,
information on the use of chemoprophylaxis is usually
based on self-reporting by the pregnant women with the
possibility of a recall bias and the risk of over-estimation of
adherence to chemoprophylaxis.
The greatest limitation on this topic, however, is the
absence of standardized data internationally and this is an
area where collaboration between reference centres and
national authorities should be pursued to achieve good
quality reporting of malaria cases and outcomes in
pregnancy.
5. Conclusions
Our data show thatmalaria chemoprophylaxis and treatment
in pregnant travellers are challenges for travelmedicinewith
varying national recommendations. The treatment of im-
portedmalaria in pregnant women does not appear to follow
clear guidelines and over 50 treatment regimens were re-
ported in this analysis. Efforts should be made to harmonize
treatment recommendations. Prospective international
surveillance databases on pregnant women using malaria
chemoprophylaxis and/or treatments should be established
to enable the evaluation of medication tolerability and
foetal outcomes in this vulnerable group.
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